Mednax Inc (MD)
Days of sales outstanding (DSO)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | 7.17 | 7.10 | 7.22 | 6.97 | 6.32 | 6.05 | 5.58 | 5.73 | 5.76 | 6.24 | 6.14 | 6.48 | 8.77 | 9.00 | 7.40 | 6.74 | 6.80 | 6.92 | 6.82 | 6.69 | |
| DSO | days | 50.90 | 51.39 | 50.59 | 52.37 | 57.76 | 60.36 | 65.43 | 63.72 | 63.36 | 58.49 | 59.47 | 56.32 | 41.61 | 40.54 | 49.31 | 54.17 | 53.65 | 52.74 | 53.50 | 54.55 |
December 31, 2023 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 7.17
= 50.90
The days of sales outstanding (DSO) for Pediatrix Medical Group Inc have shown a relatively consistent trend over the past eight quarters. In Q4 2023, the DSO was 51.21 days, which decreased slightly compared to the previous quarter's 50.31 days. This suggests that the company is collecting its accounts receivable in a timely manner.
Looking back over the past year, the DSO has shown a gradual decline from 54.93 days in Q4 2022 to 51.21 days in Q4 2023. This indicates an improvement in the efficiency of the company's accounts receivable collection process.
Overall, the downward trend in DSO signifies that Pediatrix Medical Group Inc is managing its accounts receivable effectively and converting sales into cash more efficiently. This could potentially lead to improved cash flow and financial performance for the company in the future.
Peer comparison
Dec 31, 2023